ZBH ZIMMER BIOMET HOLDINGS, INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1136869 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY-4.7%
TTM EPS YoY-1.7%
Revenue 3-yr CAGR5.6%
Net income 3-yr CAGR17.4%
Margins
Gross margin69.7%
Operating margin13.6%
Net margin9.0%
FCF margin19.2%
EBITDA margin26.5%
Returns
ROE6.0%
ROA3.3%
ROIC (approx.)5.1%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets45.9%
Debt / equity0.59x
Current ratio1.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.46x
Accruals ratio-4.8%
Payout ratio24.3%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B |
| Cost of revenue | $2.49B | $2.19B | $2.08B | $2.02B | $1.96B |
| Gross profit | $5.74B | $5.49B | $5.31B | $4.92B | $4.87B |
| R&D expense | $458.50M | $437.40M | $458.70M | $406.00M | $435.80M |
| SG&A expense | $3.26B | $2.93B | $2.84B | $2.76B | $2.84B |
| Operating income | $1.10B | $1.29B | $1.28B | $696.30M | $860.30M |
| Pretax income | $830.80M | $1.04B | $1.07B | $403.50M | $499.00M |
| Income tax | $125.70M | $131.40M | $42.20M | $112.30M | $53.50M |
| Net income | $705.10M | $903.80M | $1.02B | $231.40M | $401.60M |
| EBITDA | $2.19B | $2.28B | $2.23B | $1.62B | $1.80B |
| EPS (basic) | 3.56 | 4.45 | 4.91 | 1.10 | 1.93 |
| EPS (diluted) | 3.55 | 4.43 | 4.88 | 1.10 | 1.91 |
| Dividends declared per share | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 |
| Weighted avg. shares (diluted) | 198.70M | 203.90M | 209.70M | 210.30M | 210.40M |
| Banking | |||||
| Net interest income | -$292.80M | -$218.00M | -$201.20M | -$164.80M | -$208.40M |
| Balance sheet | |||||
| Cash & equivalents | $591.90M | $525.50M | $415.80M | $375.70M | $378.10M |
| Receivables | $1.70B | $1.48B | $1.44B | $1.38B | $1.26B |
| Inventory | $2.29B | $2.24B | $2.39B | $2.15B | $2.15B |
| Current assets | $5.12B | $4.67B | $4.61B | $4.43B | $4.88B |
| PP&E, net | $2.21B | $2.05B | $2.06B | $1.87B | $1.84B |
| Goodwill | $9.95B | $8.95B | $8.82B | $8.58B | $8.92B |
| Intangibles | $4.72B | $4.60B | $4.86B | $5.06B | $5.53B |
| Total assets | $23.09B | $21.37B | $21.50B | $21.07B | $23.46B |
| Current liabilities | $2.58B | $2.45B | $2.86B | $2.36B | $3.47B |
| Short-term debt | $587.10M | $863.00M | $900.00M | $544.30M | $1.61B |
| Long-term debt | $6.93B | $5.34B | $4.87B | $5.15B | $1.00B |
| Total debt | $7.52B | $6.20B | $5.77B | $5.70B | $2.61B |
| Total liabilities | $10.39B | $8.89B | $9.01B | $9.04B | $10.79B |
| Shareholders' equity | $12.70B | $12.47B | $12.48B | $12.02B | $12.66B |
| Net debt | $6.93B | $5.68B | $5.35B | $5.32B | $2.23B |
| Cash flow statement | |||||
| Operating cash flow | $1.70B | $1.50B | $1.58B | $1.36B | $1.40B |
| Capital expenditure | $224.50M | $203.80M | $291.10M | $187.90M | $143.60M |
| Free cash flow | $1.47B | $1.30B | $1.29B | $1.17B | $1.26B |
| Investing cash flow | -$1.98B | -$888.10M | -$778.90M | -$522.00M | -$443.30M |
| Financing cash flow | $326.00M | -$484.50M | -$763.50M | -$775.70M | -$1.31B |
| Depreciation & amortization | $1.09B | $996.30M | $951.70M | $926.40M | $937.70M |
| Stock-based compensation | $90.20M | $101.00M | $99.80M | $105.00M | $76.00M |
| Dividends paid | $190.30M | $196.00M | $200.90M | $201.20M | $200.10M |
| Share buybacks | $487.00M | $868.00M | $692.20M | $126.40M | — |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.